IGMS
Price:
$8.89
Market Cap:
$528.64M
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prot...[Read more]
Industry
Biotechnology
IPO Date
2019-09-18
Stock Exchange
NASDAQ
Ticker
IGMS
According to IGM Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 531.62M. This represents a change of -9.23% compared to the average of 585.70M of the last 4 quarters.
The mean historical Enterprise Value of IGM Biosciences, Inc. over the last ten years is 671.24M. The current 531.62M Enterprise Value has changed 7.82% with respect to the historical average. Over the past ten years (40 quarters), IGMS's Enterprise Value was at its highest in in the June 2021 quarter at 2.54B. The Enterprise Value was at its lowest in in the September 2019 quarter at -108359885.00.
Average
671.24M
Median
362.70M
Minimum
10.21M
Maximum
2.49B
Discovering the peaks and valleys of IGM Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.24%
Maximum Annual Enterprise Value = 2.49B
Minimum Annual Increase = -64.71%
Minimum Annual Enterprise Value = 10.21M
Year | Enterprise Value | Change |
---|---|---|
2023 | 362.70M | -42.12% |
2022 | 626.60M | -28.58% |
2021 | 877.39M | -64.71% |
2020 | 2.49B | 671.79% |
2019 | 322.10M | 2.24% |
2018 | 13.79M | 35.02% |
The current Enterprise Value of IGM Biosciences, Inc. (IGMS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
622.23M
5-year avg
934.94M
10-year avg
671.24M
IGM Biosciences, Inc.’s Enterprise Value is less than Avidity Biosciences, Inc. (4.80B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Cullinan Oncology, Inc. (630.54M), greater than Mineralys Therapeutics, Inc. (523.81M), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Design Therapeutics, Inc. (290.40M), greater than Werewolf Therapeutics, Inc. (-1378920.00), greater than Ikena Oncology, Inc. (45.73M), greater than Stoke Therapeutics, Inc. (457.69M), less than Gracell Biotechnologies Inc. (5.61B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Erasca, Inc. (747.42M), greater than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (9.43B), greater than Black Diamond Therapeutics, Inc. (139.97M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (24.72M),
Company | Enterprise Value | Market cap |
---|---|---|
4.80B | $5.16B | |
8.24B | $8.19B | |
630.54M | $730.17M | |
523.81M | $621.09M | |
439.72M | $521.60M | |
290.40M | $318.21M | |
-1378920.00 | $84.67M | |
45.73M | $82.52M | |
457.69M | $605.41M | |
5.61B | $989.87M | |
138.26M | $181.50M | |
747.42M | $763.36M | |
79.12M | $58.11M | |
9.43B | $9.55B | |
139.97M | $143.73M | |
-8620212.00 | $3.57M | |
24.72M | $31.19M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IGM Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like IGM Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is IGM Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for IGM Biosciences, Inc. (IGMS)?
What is the 3-year average Enterprise Value for IGM Biosciences, Inc. (IGMS)?
What is the 5-year average Enterprise Value for IGM Biosciences, Inc. (IGMS)?
How does the current Enterprise Value for IGM Biosciences, Inc. (IGMS) compare to its historical average?